Tag - PYXS

Developments

Pyxis Oncology to acquire Apexigen

Pyxis Oncology (NASDAQ:PYXS) agreed to acquire Apexigen (NASDAQ:APGN) in an all-stock transaction for an implied value of 64 cents per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares...

May 24, 2023

Markets

WB starts Pyxis Oncology at OP; $30 fair value estimate

William Blair launched coverage of Pyxis Oncology (NASDAQ:PYXS) with an “outperform” rating and fair value estimate of $30. The stock closed at $13.30 on Nov. 1. Pyxis Oncology is developing next-generation antibody...

November 2, 2021

Tag - PYXS

Pyxis Oncology to acquire Apexigen

WB starts Pyxis Oncology at OP; $30 fair value estimate

General

More